Molecular characterization of two monoclonal antibodies specific for the LDL receptor-binding site of human apolipoprotein E. 1995

R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
Lipoprotein and Atherosclerosis Group, University of Ottawa Heart Institute, Canada.

Apolipoprotein E (apoE), a 299 amino acid protein, is a ligand for the low density lipoprotein receptor (LDLr). It has been established that basic amino acids situated between apoE residues 136 and 150 participate in the interaction of apoE with the LDLr. Evidence suggests that apoE is heterogeneous on lipoproteins in its conformation and in its ability to react with cell surface receptors. Our goal was to produce mAbs that could serve as conformational probes of the LDLr binding site of apoE. We used a series of apoE variants that have amino acid substitutions at residues 136, 140, 143, 144, 145, 150, 152, and 158 to identify the epitopes of two anti-human apoE monoclonal antibodies (mAbs), 1D7 and 2E8, that inhibit apoE-mediated binding to the LDLr. We show that most of the variants that have reduced reactivity with the LDL receptor also have reduced reactivity with the mAbs. The epitopes for both mAbs appear to include residues 143 through 150 and thus coincide with the LDLr-binding site of apoE. It is notable that mAb 2E8, but not 1D7, resembles the LDLr in showing a reduced reactivity with apoE (Arg158 --> Cys). While most of the receptor-defective variants involve replacement of apoE residues directly implicated in binding, substitution of Arg158 by Cys is thought to indirectly affect binding of apoE to the LDLr by altering the conformation of the receptor-binding site. To determine whether the similarity in specificities of the mAbs and the LDLr reflect structural similarities, we cloned and characterized the cDNAs encoding the light and heavy chains of both mAbs. Primary sequence analysis revealed that, although these two antibodies react with overlapping epitopes, their respective complementarity determining regions (CDRs) share little homology, especially those of their heavy chains. The two mAbs, therefore, likely recognize different epitopes or topologies within a limited surface of the apoE molecule. Four negatively charged amino acids were present in the second CDR of the 2E8 heavy chain that could be approximately aligned with acidic amino acids within the consensus sequence of the LDLr ligand-binding domain. This could indicate that mAb 2E8 and the LDLr use a common mode of interaction with apoE.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011973 Receptors, LDL Receptors on the plasma membrane of nonhepatic cells that specifically bind LDL. The receptors are localized in specialized regions called coated pits. Hypercholesteremia is caused by an allelic genetic defect of three types: 1, receptors do not bind to LDL; 2, there is reduced binding of LDL; and 3, there is normal binding but no internalization of LDL. In consequence, entry of cholesterol esters into the cell is impaired and the intracellular feedback by cholesterol on 3-hydroxy-3-methylglutaryl CoA reductase is lacking. LDL Receptors,Lipoprotein LDL Receptors,Receptors, Low Density Lipoprotein,LDL Receptor,LDL Receptors, Lipoprotein,Low Density Lipoprotein Receptor,Low Density Lipoprotein Receptors,Receptors, Lipoprotein, LDL,Receptor, LDL,Receptors, Lipoprotein LDL
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003488 Cyanogen Bromide Cyanogen bromide (CNBr). A compound used in molecular biology to digest some proteins and as a coupling reagent for phosphoroamidate or pyrophosphate internucleotide bonds in DNA duplexes. Bromide, Cyanogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
July 1981, The Journal of clinical investigation,
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
August 1991, Biulleten' eksperimental'noi biologii i meditsiny,
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
January 1985, The Journal of biological chemistry,
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
October 1983, The Journal of biological chemistry,
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
June 1991, Science (New York, N.Y.),
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
March 1993, The Biochemical journal,
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
October 1983, The Journal of biological chemistry,
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
June 1999, Protein expression and purification,
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
June 1999, Protein engineering,
R Raffai, and R Maurice, and K Weisgraber, and T Innerarity, and X Wang, and R MacKenzie, and T Hirama, and D Watson, and E Rassart, and R Milne
April 2018, Heliyon,
Copied contents to your clipboard!